secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000950170-23-062943
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon Q3 net loss $32.5M, cash $165.3M; Phase 3 GBS enrollment complete, data H1 2024
--------------------------------------------------------------------------------

- Net loss of $32.5M ($0.43 per share) vs $35.1M ($1.42 per share) in Q3 2022.
- Cash, equivalents and investments of $165.3M as of Sep 30, 2023; runway into Q2 2025.
- R&D expenses flat at $27.9M; G&A down to $6.9M from $8.2M.
- Phase 3 GBS trial enrolled 225 patients; topline pivotal data expected first half 2024.
- ANX007 for GA granted EMA PRIME designation; global Phase 3 regulatory discussions ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000095017023062943/0000950170-23-062943-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000095017023062943/annx-20231113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062943

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer